Современная онкология (Jun 2013)

Prognostic value of p53 expression in patients with stage I breast cancer

  • I V Kolyadina,
  • I V Poddubnaya,
  • C JH Van de Velde,
  • P JK Kuppen,
  • G J Liefers,
  • N G Dekker-Ensink,
  • E Bastiaannet,
  • A Van As-Sajet,
  • B Prinse,
  • C Engels,
  • R Van Vlierberghe,
  • D V Komov,
  • A I Karseladze,
  • V D Ermilova,
  • Ya V Vishnevskaya,
  • G A Frank,
  • S M Banov

Journal volume & issue
Vol. 15, no. 2
pp. 17 – 21

Abstract

Read online

The prognostic value of p53 nuclear expression in Stage 1 (T1N0M0) breast cancer was studied in 315 women treated in Russia (at the N.N.Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, and at the Clinic of the Russian Medical Academy of Postgraduate Education) in 1985 to 2009. An immunohistochemical assay for determining the expression of estrogen receptors (ER), progesterone receptors (PR), and HER2 and the nuclear expression of p53 receptors was carried out at the Leiden University Medical Center. p53 nuclear expression was found in 14,7% of cases and statistically significantly correlated (p0,05) of p53 expression for the risk of further progression and death. It was suggested that the negative impact of p53 expression in the entire group might be compensated for by the positive role of adjuvant systemic therapy. Subgroup analysis showed that the patients with p53-positive tumors who did not receive any adjuvant drug treatment had the worst relapse-free and cancer-specific survival rates (p

Keywords